Discussion
type 2 diabetes, diabetic, hypoglycemic
TYPE 2 DIABETES
Type 2 diabetic patients account for more than 90% of all diabetic patients. Many patients with type 2 diabetes might not have a complete loss of insulin secretion, and some might have excessive insulin secretion (In our study, both short-acting and long-acting GLP-1 receptor agonists can reduce the levels of FPG, 2hPG, and HbAlc, which is consistent with previous studies (In response to the expensive price and relatively low-cost performance of Liraglutide, Dulaglutide has begun to be used clinically (Pharmacoeconomics is the specific application of economic principles and methods in pharmaceuticals (In previous studies, it was found that the economic benefit of dulaglutide is higher than that of liraglutide in the short term, but the long-term economic benefit is still unclear. Our research results extend the previous results (Therefore, patients with type 2 diabetes should be treated to improve relevant glucose and insulin indices then, appropriate hypoglycemic drugs should be selected in combination with their economic status and family background, to improve the pertinent treatment.